Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

NCT04773678 is registered in ClinicalTrials.gov with Connect Biopharm LLC as lead sponsor.

NCT NCT04773678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Efficacy and Safety Study of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation
Lead sponsor
Connect Biopharm LLC
Phase
Phase 2
Overall status
Completed
Start date
May 11, 2021
Completion date
September 28, 2023
Enrollment
322 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe persistent asthma